参考文献/References:
[1] Jarrar M,Behl S,Manyam G,et al.Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy[J].Mol Biol Rep,2016,43(6):473-484.
[2] Chaudhry AS,Prasad B,Shirasaka Y,et al.The CYP2C19 intron 2 branch point SNP is the ancestral polymorphism contributing to the poor metabolizer phenotype in livers with CYP2C19*35 and CYP2C19*2 alleles[J].Drug Metab Dispos,2015,43(8):1226-1235.
[3] Sibbing D,Koch W,Gebhard D,et al.Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J].Circulation,2010,121(4):512-518.
[4] Fricke-Galindo I,Cespedes-Garro C,Rodrigues-Soares F,et al.Interethnic variation of CYP2C19 alleles, `predicted' phenotypes and `measured' metabolic phenotypes across world populations[J].Pharmacogenomics Journal,2016,16(2):113-123.
[5] Ned MR.Genetic testing for CYP450 polymorphisms to predict response to clopidogrel:current evidence and test availability.Application:pharmacogenomics[J].PLoS Curr,2010,2(20):1180.
[6] Ma TK,Lam YY,Tan VP,et al.Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel[J].Pharmacol Ther,2010,125(2):249-259.
[7] Pedersen RS,Nielsen F,Stage TB,et al.CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel[J].Clin Exp Pharmacol Physiol,2014,41(11):870-878.
[8] De Andres F,Sosa-Macias M,Llerena A.A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2,CYP2C9,CYP2C19,CYP2D6 and CYP3A4 hydroxylation capacity[J].Bioanalysis,2014,6(5):683-696.
[9] Dorado P,Lopez-Torres E,Penas-Lledo E,et al.Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms[J].Pharmacogenomics Journal,2013,13(4):359-361.
[10] Chang M,Soderberg MM,Scordo MG,et al.CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy[J].Eur J Clin Pharmacol,2015,71(4):433-439.
[11] Stathopoulou MG,Monteiro P,Shahabi P,et al.Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285[J].Int J Cardiol,2013,168(3):3057-3058.
[12] Medhora M,Dhanasekaran A,Gruenloh SK,et al.Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids[J].Prostaglandins Other Lipid Mediat,2007,82(1/4, SI):19-29.
[13] Shahabi P,Siest G,Meyer UA,et al.Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders[J].Pharmacol Ther,2014,144(2):134-161.
[14] 谷树珍,李新,孙岩,等.CYP2C19基因多态性与中国汉族人群缺血性脑卒中的发病有关[A].中华医学会、中华医学会神经病学分会.中国脑血管病大会2014论文汇编[C].中华医学会、中华医学会神经病学分会,2014:2.
[15] Hokimoto S,Tabata N,Akasaka T,et al.Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease[J].J Cardiovasc Pharmacol,2015,65(2):148-152.
[16] Sim SC,Kacevska M,Ingelman-Sundberg M.Pharmacogenomics of drug-metabolizing enzymes:a recent update on clinical implications and endogenous effects[J].Pharmacogenomics J,2013,13(1):1-11.
[17] Persson A,Sim SC,Virding S,et al.Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene[J].Mol Psychiatry,2014,19(6):733-741.
[18] Penas-Lledo E,Guillaume S,Naranjo M,et al.A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances[J].Pharmacogenomics Journal,2015,15(2):172-176.
[19] Kazui M,Nishiya Y,Ishizuka T,et al.Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
[20] Qureshi Z,Hobson AR.Clopidogrel"resistance":where are we now?[J].Cardiovasc Ther,2013,31(1):3-11.
[21] Cuisset T,Cayla G,Silvain J.Clopidogrel resistance: what's new?[J].Arch Cardiovasc Dis,2010,103(6/7):349-353.
[22] 孙弋,华尉利,杨劲.血小板功能检测指标的研究进展及其在新药研发中的应用[J].中国临床药理学杂志,2016,32(16):1531-1536.
[23] Müller I,Besta F,Schulz C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement[J].Thromb Haemost,2003,89(5):783-787.
[24] Siller-Matula JM,Trenk D,Schror K,et al.Response variability to P2Y12 receptor inhibitors:expectations and reality[J].JACC Cardiovasc Interv,2013,6(11):1111-1128.
[25] Nguyen TA,Diodati JG,Pharand C.Resistance to clopidogrel: A review of the evidence[J].J Am Coll Cardiol,2005,45(8):1157-1164.
[26] Wu ZK,Wang JJ,Wang T,et al.Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity[J].J Geriatr Cardiol,2015,12(4):378-382.
[27] Shuldiner AR,O'connell JR,Bliden KP,et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA,2009,302(8):849-857.
[28] Chen M,Liu XJ,Yan SD,et al.Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease[J].Atherosclerosis,2012,220(1):168-171.
[29] Jia DM,Chen ZB,Zhang MJ,et al.CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China[J].Stroke,2013,44(6):1717-1719.
[30] Tsantes AE,Ikonomidis I,Papadakis I,et al.Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays[J].Thromb Res,2013,132(2):e105-e111.
[31] Saydam F,De(ˇoverg)irmenci i,Birdane A,et al.The CYP2C19*2 and CYP2C19*17 polymorphisms play a vital role in clopidogrel responsiveness after percutaneous coronary intervention: a pharmacogenomics study[J].Basic Clin Pharmacol Toxicol,2017,121(1):29-36.
[32] Liu Y,Liu N,Li W,et al.Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention[J].Pharmacology,2013,91(3/4):165-172.
[33] Wang Y,Cai H,Zhou G,et al.Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel[J].J Neurol Sci,2016,369(369):216-219.
[34] Nagashima Z,Tsukahara K,Morita S,et al.Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes[J].J Cardiol,2013,62(3):158-164.
[35] 谢婧,胡欣,杨莉萍.CYP2C19*17多态性对氯吡格雷临床疗效影响的系统评价[J].中国循证医学杂志,2014,14(3):271-276.